H.C. Wainwright analyst Brandon Folkes has maintained their bullish stance on RANI stock, giving a Buy rating on July 10.

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Brandon Folkes has given his Buy rating due to a combination of factors that highlight both strategic progress and underappreciated asset value at Rani Therapeutics. The newly announced collaboration with PegBio expands RANI’s reach in obesity and metabolic disease, adds several promising peptide-based programs, and importantly reinforces external confidence in the RaniPill oral-delivery platform as a partner-ready technology.

Folkes also points to three distinct value drivers that the market is not fully recognizing: RANI’s internal pipeline led by the Phase I obesity candidate RT-114, the Chugai partnership that offers non-dilutive funding and potential expansion to multiple additional targets, and the ability to layer on further collaborations like PegBio to build a broad pipeline without heavy discovery spend. Taken together, these elements support his unchanged $11 price target and justify maintaining a Buy rating as RANI positions itself as a preferred oral-delivery partner for injectable biologics in large, growing markets.

Folkes covers the Healthcare sector, focusing on stocks such as Heron Therapeutics, Traws Pharma, and Zevra Therapeutics. According to TipRanks, Folkes has an average return of 0.0% and a 40.48% success rate on recommended stocks.

In another report released on July 10, Canaccord Genuity also maintained a Buy rating on the stock with a $5.00 price target.